NCT05924503

Brief Summary

There is a dire need to establish normative values for transcranial Doppler(TCD) derived cerebral blood flow parameters for each type of Mechanical circulatory support (MCS) device and explore the relationship between the MCS device's systemic flow dynamics and TCD based cerebral flow(CBF) parameters TCD derived cerebral blood flow parameters can then be investigated as targets used to titrate systemic flow dynamics from MCS. Having target flow rates titrated to patient specific condition using TCD may help avoid both hypoperfusion as well as the possibility of hyperemia reperfusion injury contributing to neurological morbidity. We propose a multicenter study to gather normative data on TCD derived CBF and MCS systemic dynamics for a wide range of patient demographics. Such data collection is only possible with multi-center collaboration given the small volume of patients with MCS patients in each center.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2024

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 13, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

June 29, 2023

Completed
11 months until next milestone

Study Start

First participant enrolled

May 22, 2024

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 22, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 22, 2025

Completed
Last Updated

April 2, 2026

Status Verified

March 1, 2026

Enrollment Period

1.6 years

First QC Date

April 13, 2023

Last Update Submit

March 27, 2026

Conditions

Keywords

hemodynamic supportTraditional neuroimaging methodsneurological complications

Outcome Measures

Primary Outcomes (4)

  • Normative range of transcranial Doppler intracranial flow velocity - Baseline

    Normal mean velocity of the intracranial blood vessels (Middle cerebral artery (MCA), Internal carotid artery (ICA) Posterior Cerebral Arteries (PCA), Anterior Cerebral Artery (ACA), Basilar and Vertebral A )is usually \< 80 cm/s in patients with normal cardiac output. We will explore the range of normal values of intracranial vessel velocity in patients with different degree/ type of MCS devices adjusted to the contribution of LV to blood flow 0-10 L/min

    Baseline

  • Normative range of transcranial Doppler intracranial flow velocity- daily up to 2 years

    Assess serial changes in intracranial vessel velocity ( MCA, ICA PCA, ACA, Basilar and Vertebral A ) that occur with changes in systemic dynamics related to change in MCS settings

    daily up to 2 years

  • Normative range of transcranial Doppler-derived pulsatility index

    Normal pulsatility index for intracranial vessels index ( MCA, ICA PCA, ACA, Basilar and Vertebral A ) is 0.6-1.2 in patients with normal cardiac output. We will describe the correlation between transcranial Doppler-derived Pulsatility index and degree/ type of mechanical circulatory support and the contribution of LV to blood flow 0-10 L/min

    Baseline

  • Normative range of transcranial Doppler-derived pulsatility index- daily up to 2 years

    Assess serial changes in transcranial Doppler-derived pulsatility index ( MCA, ICA PCA, ACA, Basilar and Vertebral A ) that occur with changes in systemic dynamics related to change in MCS settings

    daily up to 2 years

Secondary Outcomes (2)

  • Number of neurological complications observed in patients enrolled in the study

    Baseline and daily up to 2 years

  • Association of abnormalities seen in cerebral blood flow assessed using transcranial Doppler-derived

    Up to 2 years

Study Arms (1)

Transcranial Doppler

Serial daily TCD during the ICU stay involving bilateral Middle cerebral artery (MCA) insonation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients admitted to the intensive care unit or inpatient wards for cardiogenic shock requiring mechanical circulatory support

You may qualify if:

  • \>18 years old on the day of enrollment
  • Mechanical circulatory support
  • a. Left Ventricular Assist Device \[HeartMate-III\] in antegrade flow i. Critically ill ii. With and without pulsatility b. Impella antegrade flow c. VA-ECMO (VA-ECMO) is a temporary mechanical circulatory support system that enables complete and immediate cardiopulmonary support in the setting of cardiogenic shock and cardiac arrest) retrograde flow usual with femoral cannulation or antegrade flow if centrally cannulated
  • Patient must be in the intensive care unit or in patient for the intervention to be performed

You may not qualify if:

  • Known cerebrovascular disease or know angiographic abnormalities based on preexisting computed tomography angiography, digital subtraction angiography or transcranial Doppler prior to this hospitalization that will significantly affect Transcranial Doppler (TCD) parameters. Patients with abnormalities not likely to affect TCD parameters or known normal TCDs despite abnormal cerebral hemodynamic studies will still be included
  • Pre-Existing neurological deficits impairing quality of life
  • Absence of temporal windows
  • Presence of skull defects that may affect the feasibility of TCD windows
  • Co-existing dialysis or other forms of renal replacement therapy
  • Pregnant patients
  • Patients on palliative care pathway awaiting de-escalation
  • Patient on comfort care

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

Location

Study Officials

  • Aarti Sarwal, MD

    Wake Forest University Health Sciences

    PRINCIPAL INVESTIGATOR
  • Connor O'Brien

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR
  • Ashish Khanna, MD

    Wake Forest University Health Sciences

    PRINCIPAL INVESTIGATOR
  • John Gaillard, MD

    Wake Forest University Health Sciences

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 13, 2023

First Posted

June 29, 2023

Study Start

May 22, 2024

Primary Completion

December 22, 2025

Study Completion

December 22, 2025

Last Updated

April 2, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
Beginning 3 months and ending 5 years following article publication.
Access Criteria
Researchers who provide a methodologically sound proposal.

Locations